|
Back to Home » April 2018 News » BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA® |
BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA® |
April 10, 2018
BERGEN, Norway, April 10, 2018 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors as a potential cornerstone of combination cancer therapy in NSCLC, AML/MDS, TNBC and melanoma, announces that it has...
Source URL: https://www.prnewswire.com/news-releases/bergenbio-completes-recruitment-into-first-stage-of-phase-ii-nsclc-trial-with-selective-axl-inhibitor-bemcentinib-combined-with-keytruda-300627003.html
|
|
|
|
